Hoth Therapeutics Announces Positive Preclinical Results for HT-KIT in Aggressive Cancer Gastrointestinal Stromal Tumors (GIST). HT-KIT Triggered Significant Tumor Cell Death as Early as 24 Hours Post-treatment

Core Insights - Hoth Therapeutics, Inc. announced breakthrough preclinical findings for HT-KIT, a novel targeted therapy for gastrointestinal stromal tumors (GIST), demonstrating significant tumor burden reduction and disruption of KIT signaling pathways [2][3][4] Group 1: Key Findings from Preclinical Study - HT-KIT triggered significant tumor cell death as early as 24 hours post-treatment, with lower doses leading to substantial cell death at 72 hours [6][7] - HT-KIT treatment inhibited cell growth and proliferation in GIST-T1 cells, confirmed by reductions in cell count and decreased fluorescence intensity in proliferation assays [6][7] - In a humanized xenograft model, HT-KIT treatment (12.5 mg/kg IV every three days) led to significant tumor growth reduction, with statistically significant differences observed by day 8 [6][7] - Excised tumors from HT-KIT-treated mice were smaller and lighter than those in the control group, reinforcing tumor volume measurements [6][7] Group 2: Treatment Mechanism and Potential - HT-KIT effectively reduced KIT receptor expression within 24 hours, with effects sustained for 72 hours [7] - By targeting KIT mutations, HT-KIT has shown remarkable efficacy in preclinical models, indicating its potential as a transformative treatment option for GIST [3][4][5] Group 3: Next Steps in Development - Hoth Therapeutics is advancing HT-KIT toward clinical evaluation, conducting additional preclinical studies to validate its efficacy and safety profile [5] - Plans are in place to initiate regulatory discussions for first-in-human trials [5]